Crossmark

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

Crossref DOI link: https://doi.org/10.1136/jitc-2020-001097

Published Online: 2020-08-24

Published Print: 2020-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Katz, Steven C

Moody, Ashley E

Guha, Prajna

Hardaway, John C https://orcid.org/0000-0002-4952-1937
Prince, Ethan

LaPorte, Jason

Stancu, Mirela

Slansky, Jill E

Jordan, Kimberly R

Schulick, Richard D

Knight, Robert

Saied, Abdul

Armenio, Vincent

Junghans, Richard P
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02850536 at ClinicalTrials.gov

Documents that mention this clinical trial

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
https://doi.org/10.1136/jitc-2020-001097
Funding

Funding for this research was provided by:

The State of Colorado Office of Economic Development

TriSalus

Clinigen Group PLC

Sorrento/TNK Therapeutics
License Information

License valid from 2020-08-24